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Abstract
Introduction: Experimental evidence suggests a protective role for circulating 25-hydroxyvitamin D (25(OH)D) in
breast cancer development, but the results of epidemiological studies have been inconsistent.
Methods: We conducted a case-control study nested within two prospective cohorts, the New York University
Women’s Health Study and the Northern Sweden Mammary Screening Cohort. Blood samples were collected at
enrollment, and women were followed up for breast cancer ascertainment. In total, 1,585 incident breast cancer
cases were individually-matched to 2,940 controls. Of these subjects, 678 cases and 1,208 controls contributed two
repeat blood samples, at least one year apart. Circulating levels of 25(OH)D were measured, and multivariate odds
ratios (ORs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression.
Results: No association was observed between circulating levels of 25(OH)D and overall breast cancer risk
(multivariate-adjusted model OR = 0.94, 95% CI = 0.76-1.16 for the highest vs. lowest quintile, ptrend = 0.30). The
temporal reliability of 25(OH)D measured in repeat blood samples was high (intraclass correlation coefficients for
season-adjusted 25(OH)D > 0.70). An inverse association between 25(OH)D levels and breast cancer risk was
observed among women who were ≤ 45 years of age (ORQ5-Q1 = 0.48, 95% CI = 0.30-0.79, ptrend = 0.01) or
premenopausal at enrollment (ORQ5-Q1 = 0.67, 95% CI = 0.48-0.92, ptrend = 0.03).
Conclusions: Circulating 25(OH)D levels were not associated with breast cancer risk overall, although we could not
exclude the possibility of a protective effect in younger women. Recommendations regarding vitamin D
supplementation should be based on considerations other than breast cancer prevention.
Introduction
Experimental studies support a role for vitamin D in redu-
cing the risk of breast cancer [1,2]. Vitamin D, which is
obtained from both dietary sources (food and supple-
ments) and exposure to type B ultraviolet radiation, under-
goes two hydroxylation steps before becoming biologically
active [3]. 25-hydroxyvitamin D [25(OH)D], produced in
the liver from the first hydroxylation, is the precursor of
the biologically active form, 1,25(OH)2D, which is pro-
duced in the kidney as well as in target tissues, including
the breast [4]. Circulating 25(OH)D is considered the best
marker of vitamin D status because it reflects vitamin D
obtained from both diet/supplements and sun exposure
[5] and has a longer half-life than 1,25(OH)2D [6]. Vitamin
D acts by binding to the vitamin D receptor (VDR), which
is expressed in mammary tissue. The VDR controls the
expression of genes regulating cell proliferation, differen-
tiation, and apoptosis [1,7].
The results of epidemiologic studies examining the asso-
ciation between circulating 25(OH)D levels and breast
cancer risk have been inconsistent. Seven prospective stu-
dies reported no association overall [8-14], whereas three
reported a significant or marginally significant inverse
association [15-17]. Some significant findings emerged
from the results of subgroup analyses, although the sub-
groups of women for whom these associations were
observed were not consistent across studies. The Nurses’
Health Study observed a stronger protective effect of
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plasma 25(OH)D on breast cancer risk for women who
were 60 years old or older [16], whereas the French E3N
cohort observed a stronger effect in women who were less
than 53 years old at enrollment [15]. In the Nurses’ Health
Study II, which consists primarily of pre-menopausal
women, no association was observed overall between
plasma 25(OH)D levels and breast cancer risk, and a posi-
tive, rather than an inverse, association was observed
among women who were overweight or obese, the latter
of which is defined as a body mass index (BMI) of at least
30 kg/m2 [13].
Recent reviews have concluded that there is insufficient
evidence to recommend vitamin D supplementation for
the prevention of breast cancer but that additional
research in humans is needed [3,18,19]. The purpose of
our study was to examine the association between pre-
diagnostic circulating levels of circulating 25(OH)D and
breast cancer risk in a case-control study nested within
two prospective cohorts: the New York University
Women’s Health Study (NYUWHS) and the Northern
Sweden Mammary Screening Cohort (NSMSC). A unique
feature of this study, the largest prospective study to date,
was the availability of two 25(OH)D measurements from
blood samples donated a minimum of one year apart for a
large proportion of the study subjects, allowing us to esti-
mate with good precision the temporal reliability of 25
(OH)D, and factors that affected it, in the two cohorts.
Materials and methods
Study population
Descriptions of the NYUWHS and the NSMSC have
been provided previously [20,21]. Briefly, the NYUWHS
cohort enrolled 14,274 healthy women (34 to 65 years
old) at a mammography screening clinic in New York
City between 1985 and 1991, and the NSMSC enrolled,
between 1995 and 2006, approximately 28,800 women
(40 to 69 years old) who are participating in a popula-
tion-based breast cancer screening program in Västerbot-
ten County, Sweden. After written informed consent was
obtained from all study participants, information on
demographic and anthropometric variables, medical and
reproductive history, family history of breast cancer, and
lifestyle factors, including diet, was collected through
baseline or subsequent questionnaires or both. Venous
blood was collected at enrollment, processed according
to standard procedures by the respective cohorts (serum
for NYUWHS and plasma for NSMSC), and stored at
-80°C. Additional blood samples were collected from
women who returned for screening. This study was
approved by the Institutional Review Board of the New
York University School of Medicine, the Regional Ethics
Committee of the University of Umeå, Sweden, and the
Swedish Data Inspection Board.
Case ascertainment and control selection
For the NYUWHS, incident cases of invasive breast cancer
were identified by mailed questionnaires or follow-up tele-
phone interviews every 2 to 4 years after 1991, supplemen-
ted by linkages to state cancer registries in New York, New
Jersey, and Florida and the US National Death Index.
Medical records were reviewed to confirm self-reported
cases. Using a capture-recapture analysis, we estimated
that combining active and cancer registry-based follow-up
resulted in a breast cancer ascertainment rate of 95% [22].
For the NSMSC, annual linkages to the Swedish National
Cancer Registry were used to identify incident cases of
breast cancer in the cohort. As of 1 January 2007 for the
NYUWHS and 1 January 2010 for the NSMSC, a total of
1,645 incident cases of invasive breast cancer (909 in the
NYUWHS and 736 in the NSMSC) had been identified. In
the NYUWHS, 16 cases (3%) were excluded because they
had a low serum balance. In the NSMSC, 44 cases (6%)
were excluded for the following reasons: 26 had low
plasma balance, 13 had their plasma reserved because of a
subsequent diagnosis of a rarer cancer or other disease,
3 had insufficient volume for laboratory measurement,
and 2 had both matched controls excluded for one of the
reasons above. The present study included a total of 1,585
incident breast cancer cases (893 from the NYUWHS and
692 from the NSMSC).
Each case was matched to two controls who were
selected from the respective cohort by using incidence-
density sampling. Matching factors included age at
enrollment in the study (± 6 months), date of enroll-
ment/first blood donation (NYUWHS: ± 3 months;
NSMSC: ± 1 month), and number (1, 2+) and dates of
subsequent blood donations. For the NYUWHS, match-
ing factors also included menopausal status (pre- or post-
menopausal) at enrollment and race/ethnicity (Caucasian,
African-American, other, or unknown). The vast majority
of women in the NSMSC were Caucasian. Initially,
women were not matched on menopausal status in this
cohort; however, 88% of the cases had at least one con-
trol matching on this factor (pre- and peri-menopausal
combined or post-menopausal). In total, 2,940 controls
were included in the final analysis (1,642 in NYUWHS
and 1,298 in NSMSC).
For 678 matched sets (413 in NYUWHS and 265 in
NSMSC), two blood samples were analyzed for 25(OH)D.
For participants who had donated more than two blood
samples, the first and last samples collected before the
relevant case’s diagnosis were selected.
Laboratory methods
Circulating 25(OH)D was measured by Heartland Assays,
Inc. (Ames, IA, USA) by using a direct competitive che-
miluminescence immunoassay by using the DiaSorin
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LIAISON platform (DiaSorin, Inc., Stillwater, MN, USA)
[23]. The assay, which is appropriate for either serum or
plasma, is co-specific for 25-hydroxyvitamin D3 and 25-
hydroxyvitamin D2. All samples, including repeat sam-
ples, from a case and her matched controls were analyzed
together in the same laboratory batch to minimize
laboratory variability. Laboratory personnel were blinded
to case-control status of the study samples. Samples from
quality-control pools (6% of total samples) were masked
and inserted randomly in the batches. The intra- and
inter-batch coefficients of variation (CVs) were 9.5% and
11.4%, respectively, for NYUWHS and 7.4% and 9.0%,
respectively, for NSMSC.
Estrone was measured by double-antibody radioimmu-
noassay with reagents from Diagnostic System Labora-
tories (Webster, TX, USA) at the Laboratory for Hormone
Analyses at the International Agency for Research on
Cancer, France, for post-menopausal women who were
not using hormone replacement therapy (HRT). Intra- and
inter-batch CVs were 6.7% and 12.6%, respectively [24,25].
Statistical analysis
We examined the temporal reliability of circulating 25(OH)
D by using the intraclass correlation coefficient (ICC). In
addition to calculating the overall ICC, we calculated ICCs
according to time (years) between sample donations and
according to season, for each cohort separately.
Conditional logistic regression was used to estimate
odds ratios (ORs) and 95% confidence intervals (CIs) for
the associations of subject characteristics and circulating
25(OH)D with risk of breast cancer. We conducted ana-
lyses separately for each cohort as well as combining
them. Because there was no evidence of cohort heteroge-
neity, most results are presented for the combined cohorts.
25(OH)D concentrations were log2-transformed to reduce
departure from the normal distribution and were included
in the model in one of three ways. First, we computed sea-
son-adjusted residuals to take into account the known var-
iations of 25(OH)D with season [3]. For each 25(OH)D
measurement, the residual was the difference between the
observed 25(OH)D value and the value predicted for this
day of the year, which was obtained by using a non-para-
metric local regression (Proc LOESS; SAS Institute Inc.,
Cary, NC, USA) with 25(OH)D as the dependent variable
and day of the year of blood donation as the independent
variable [26]. This regression model was run separately for
each cohort by using all available 25(OH)D measurements
(that is, including repeat samples). We conducted analyses
by using cohort-specific season-adjusted quintiles based
on the distribution of the residuals in controls. Second, we
ran analyses with season-adjusted residuals on the contin-
uous scale. All analyses based on residuals were conducted
by using first (that is, baseline) samples only. Finally, we
examined the association of circulating 25(OH)D with
breast cancer risk by using pre-specified categories of 25
(OH)D levels, which were defined by using cut-points
recommended by the Institute of Medicine: less than 50
(inadequate), 50 to 74 (adequate), and at least 75 nmol/L
(adequate to high) [3]. These analyses were conducted
separately for ‘winter’ and ‘summer’, which were defined by
examining the unadjusted 25(OH)D levels in controls
within each cohort. Winter included the months of January
to April, when mean levels were low (48.1 to 51.2 nmol/L),
and summer included the months of July to September,
when mean levels were high (62.0 to 68.0 nmol/L). There
was little variation in mean level from month to month
within each of these two seasons. Subjects who had mea-
surements in both winter and summer were included in
both season-specific analyses to increase the sample size.
Because there was no difference in the main study findings
between conditional logistic regression models and uncon-
ditional models adjusting for the matching factors and
because using conditional regression resulted in the loss of
matched sets with samples collected in different seasons
for the case and her controls, unconditional logistic regres-
sion was used for the season-specific analyses. In analyses
by quintiles and pre-specified categories, tests for trend
were performed by using an ordered categorical variable.
Tests for heterogeneity were carried out by comparing
models that included interaction terms to models that
excluded them or by using Cochran’s Q statistic.
In each of the two cohorts, multivariate linear regres-
sion analyses were conducted among the controls to
explore associations of potential confounders with 25
(OH)D. BMI was found to be a negative predictor of 25
(OH)D, whereas multivitamin supplement use and past
use of HRT were positive predictors in both cohorts.
Caucasian race and physical activity were also positive
predictors of 25(OH)D in the NYUWHS, and alcohol
consumption was a negative predictor in the NSMSC.
Covariates in the final multivariate models included the
following known breast cancer risk factors: age at
menarche (continuous), age at first birth/parity (not
more than 20, 21 to 15, 26 to 30, more than 30 years,
nulliparous), family history of breast cancer (no or yes),
BMI (continuous), past HRT use (never or ever), and
alcohol consumption. It is debatable whether to control
for outdoor physical activity and multivitamin use,
which have been associated with higher levels of circu-
lating 25(OH)D [27,28] since these variables may influ-
ence breast cancer risk through their effect on 25(OH)D
levels. However, these factors may affect breast cancer
risk through other mechanisms [29], in which case they
could act as possible confounders in analyses of 25(OH)
D and breast cancer risk. Therefore, in addition to pre-
senting models adjusting for the factors listed above, we
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present results adjusting for physical activity and multi-
vitamin use (no or yes). In the NYUWHS, physical
activity was expressed as metabolic equivalent of task-
hours per week (MET-hours/week) from walking and
vigorous exercise, and women were classified into ter-
tiles. In the NSMSC, women were classified as inactive,
moderately active, or active by combining data on physi-
cal activity at work and frequency of walking, biking,
and exercising. Baseline data were used for all variables
except HRT in the NYUWHS, which represented use
up to the date of diagnosis (or index date for controls).
We performed multiple imputation by using fully con-
ditional specification [30] for the following covariates
with missing data: alcohol consumption (23%), physical
activity (23%), multivitamin use (18%), HRT use (6%),
age at menarche, parity, age at first full-term pregnancy,
and BMI (all with not more than 2% missing data). We
compared analyses including all subjects and imputed
data for covariates to analyses including only subjects
with no missing data (complete case method). Because
results from both analyses were similar, we present only
the analyses that included all subjects and imputed data.
We conducted stratified analyses by using conditional
logistic regression for the following variables: age at enroll-
ment, lag-time between blood donation and diagnosis, and
estrogen receptor (ER) status. In order not to lose the
matched sets in which a case and her controls were discor-
dant, unconditional logistic regression, adjusted for cohort
and age at blood sampling, was performed for the follow-
ing variables: menopausal status, BMI, circulating estrone
levels (for post-menopausal women only), and insulin-like
growth factor 1 (IGF-I) levels. Tertiles were used for the
IGF-1 analysis because of the limited number of women
for whom IGF-1 had been measured (193 cases and 269
controls from the NYUWHS only). Finally, we performed
an analysis limited to Caucasians (90% of subjects). All sig-
nificance testing was two-sided, and a P value of less than
0.05 was considered statistically significant.
Results
Descriptive statistics for the breast cancer cases and their
matched controls are presented in Table 1. Mean age at
enrollment was 54 years for both cases and controls.
Cases were diagnosed an average of 8.7 years after blood
donation. Established risk factors for breast cancer -
including younger age at menarche, nulliparity, older age
at first full-term pregnancy, and having a first-degree
family history of breast cancer - occurred more com-
monly in cases. Cases were more likely to report having
used HRT. BMI was significantly different between cases
and controls in post-menopausal women, among whom a
greater proportion of cases were overweight and obese.
Among the 77% of cases for which receptor status was
known, 78% of tumors were ER-positive.
For women who donated more than one blood sample,
the average time between sample donations was 2.1 years in
the NYUWHS and 4.4 years in the NSMSC. Overall, the
temporal reliability of 25(OH)D was good (ICC = 0.65, 95%
CI 0.61 to 0.69 for NSMSC and 0.78, 95% CI 0.76 to 0.80 for
NYUWHS) and improved for NSMSC when season-
adjusted residuals were used (ICC = 0.71, 95% CI 0.67 to
0.74) (Table 2). The ICC for the NYUWHS was not changed
by seasonal adjustment, because women in the NYUWHS
generally returned to the screening center and donated a
blood sample at the same time each year. We observed that
the ICC decreased as time increased between sample dona-
tions, although this trend did not appear to extend beyond
the first 8 years. For the NSMSC, the season-adjusted ICCs
were 0.56 (95% CI = 0.42 to 0.68) for samples collected
5 to 8 years apart (n = 113 subjects) and 0.63 (95% CI = 0.51
to 0.74) for samples collected between 8 and 11.7 years
apart (n = 106 subjects). For both cohorts, the ICC was
substantially lower when one sample was donated in the
winter and the other one in the summer months (ICC =
0.47, 95% CI = 0.29 to 0.61 for NSMSC, n = 92; ICC = 0.66,
95% CI = 0.50 to 0.77 for the NYUWHS, n = 68).
Table 3 reports ORs and 95% CIs for breast cancer risk
according to season-adjusted quintiles of 25(OH)D. There
was no association between circulating vitamin D and
breast cancer risk overall (adjusted model ORQ5-Q1 = 0.94,
95% CI = 0.76 to 1.16, Ptrend = 0.30) or within either
cohort. Results with 25(OH)D on the continuous scale
were similar. Adjusting for physical activity and multivita-
min use, in addition to the other confounders, did not
materially affect the results (ORQ5-Q1 = 0.94, 95% CI =
0.76 to 1.16, Ptrend = 0.27).
In analyses using pre-specified categories of circulating
25(OH)D (not adjusted for season), we observed no asso-
ciation with breast cancer risk for samples taken either in
the winter, when more than half of the subjects had levels
below 50 nmol/L, or in the summer, when more of the
subjects had levels more than 75 nmol/L (Table 4). A
suggestive protective effect was observed for women in the
NYUWHS who donated blood in the summer months
(OR = 0.69, 95% CI = 0.45 to 1.07, Ptrend = 0.10 for con-
centrations of at least 75 versus less than 50 nmol/L), but
no such association was observed in the NSMSC.
Table 5 shows the results of subgroup analyses. Higher
circulating 25(OH)D was associated with a decreased risk
of breast cancer among women who were pre-menopausal
at blood donation (ORQ5-Q1 = 0.67, 95% CI = 0.48 to 0.92,
Ptrend = 0.03) but not among those who were post-meno-
pausal (ORQ5-Q1 = 1.21, 95% CI = 0.92 to 1.58, Ptrend =
0.67, Pinteraction = 0.05). A similar protective effect was
observed for women who were not more than 45 years old
at blood donation (ORQ5-Q1 = 0.48, 95% CI = 0.30 to 0.79,
Ptrend = 0.01, Pinteraction = 0.08). There was no evidence of
effect modification by ER status of the tumor, lag-time
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Age at enrollment, years
≤ 45 301 (19%) 575 (20%)
46-54 557 (35%) 1,005 (34%) Matched
≥ 55 727 (46%) 1,360 (46%)
Age at diagnosis, years
≤ 55 393 (25%)
56-64 511 (32%)
≥ 65 681 (43%)
Race
Caucasian 1,370 (90%) 2,484 (90%)
African-American 94 (6%) 163 (6%) Matched
Other 51 (4%) 118 (4%)
Missing 70 175
Education
Some high school or less 288 (25%) 582 (26%)
Completed high school 415 (36%) 820 (37%) 0.09
College or higher 439 (38%) 801 (36%)
Missing 443 737
Menopausal status at enrollment
Pre- or peri-menopausal 637 (40%) 1,134 (39%) Matchedb
Post-menopausal 948 (60%) 1,806 (61%)
Age at menarche, years
< 12 285 (18%) 477 (17%)
12 397 (26%) 670 (23%)
13 439 (28%) 803 (28%) 0.005
> 13 438 (28%) 926 (32%)
Missing 26 64
Nulliparous 327 (21%) 530 (18%) 0.029
Missing 46 63
Age at first full-term pregnancy,
years
≤ 20 171 (14%) 409 (18%)
21-25 523 (44%) 1,016 (44%)
26-30 318 (27%) 596 (26%) 0.006
> 30 172 (15%) 281 (12%)
Missing 28 45
Ever user of oral contraceptives 677 (46%) 1219 (45%) 0.45
Missing 121 209
Ever user of hormone
replacement therapy
445 (30%) 685 (25%) < 0.001
Missing 99 176
First-degree family history of
breast cancer
299 (19%) 437 (15%) 0.0005
Body mass index, kg/m2
Pre- and peri-menopausal
< 20.0 53 (8%) 104 (9%)
20.0-24.9 339 (54%) 614 (55%) 0.24
≥ 25.0 237 (38%) 409 (36%)
Missing 8 7
Post-menopausal
< 20.0 31 (3%) 78 (4%)
20.0-24.9 396 (43%) 848 (48%)
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Table 1 Characteristics of breast cancer cases and matched controls (Continued)
≥ 25.0 498 (54%) 835 (48%) 0.0009
Missing 23 45
Multivitamin user 515 (41%) 956 (39%) 0.49
Missing 332 509
Ever smoker 642 (50%) 1,264 (52%) 0.52
Missing 299 524
Alcohol, drinks per day
0 501 (43%) 928 (41%)
< 1 552 (47%) 1,161 (51%)





< 5.5 249 (31%) 412 (28%)
5.5-21.5 271 (34%) 506 (35%) 0.12




Inactive 55 (14%) 107 (13%)
Moderately active 145 (37%) 305 (37%)
Active 192 (49%) 408 (50%) 0.84
Missing 300 478
Dietary vitamin D in IU/day,
median (10th-90th percentile)
141 (55, 272) 145 (55, 275) 0.60
Missing 340 526
Circulating 25(OH)D in nmol/L,
median (10-90th percentile)
53.0 (31.2, 81.0) 54.2 (30.7, 82.6) 0.27
aP value from conditional logistic regression (P value from trend test for ordered categories). bMenopausal status (pre- or post-menopausal) was a matching
factor for all sets in the New York University Women’s Health Study (NYUWHS). For Northern Sweden Mammary Screening Cohort (NSMSC), women were not
initially matched on this factor, and 88% of the cases had at least one control matched on menopausal status (pre- and peri-menopausal combined or post-
menopausal). 25(OH)D, 25-hydroxyvitamin D; MET, metabolic equivalent of task.
Table 2 Intraclass correlation coefficients by time between sample donation (years) and by season (NSMSC and
NYUWHS)
NSMSC NYUWHS
Number of subjects ICC (95% CI) Number of subjects ICC (95% CI)
Alla 700 0.65 (0.61, 0.69) 1,168 0.78 (0.76, 0.80)
Allb 700 0.71 (0.67, 0.74) 1,168 0.78 (0.76, 0.80)
Time between samplesb, years
≤ 1 393 0.80 (0.76, 0.83)
> 1-2 146 0.79 (0.71, 0.84) 325 0.81 (0.77, 0.84)
> 2-3 139 0.81 (0.75, 0.86) 208 0.80 (0.75, 0.84)
> 3-5 196 0.71 (0.63, 0.73) 214 0.74 (0.67, 0.79)
> 5-8 113 0.56 (0.42, 0.68)
> 8-11.7 106 0.63 (0.51, 0.74)
Seasonsa
Both samples in winter 148 0.74 (0.66, 0.81) 266 0.78 (0.72, 0.82)
Both samples in summer 53 0.79 (0.67, 0.88) 210 0.81 (0.76, 0.85)
One sample in winter, one in summer 92 0.47 (0.29, 0.61) 68 0.66 (0.50, 0.77)
aLog2-transformed 25(OH)D values.
bSeason-adjusted 25(OH)D residual values. 25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; ICC, intraclass correlation
coefficient; NSMSC, Northern Sweden Mammary Screening Cohort; NYUWHS, New York University Women’s Health Study.
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between blood sampling and diagnosis, BMI, or circulating
estrone levels. Results of the analysis limited to Caucasians
were similar to those of the analysis that included all
subjects.
When we examined the association of 25(OH)D with
breast cancer risk by IGF-1 levels at baseline, the ORs
for the third tertile were 0.62 (95% CI = 0.30 to 1.28)
in the below-median stratum and 0.79 (95% CI = 0.39
to 1.62) in the above-median stratum. The test for
interaction between IGF-1 and 25(OH)D on the
continuous scale was not statistically significant
(P = 0.61).
Table 4 Odds ratios and 95% confidence intervals for breast cancer risk according to pre-specified categories of
circulating 25(OH)D concentration by seasona
Pre-specified categories, nmol/L Continuousb P value
< 50 50-74 75+ Ptrend
Winter (Jan., Feb., March, April)
Both cohortsc Cases/controls 391/704 244/472 65/116
OR (95% CI) 1.0 (ref) 0.94 (0.77, 1.15) 1.06 (0.76, 1.48) 0.95 0.97 (0.82, 1.15) 0.74
NYUWHS Cases/controls 193/331 105/217 35/65
OR (95% CI) 1.0 (ref) 0.82 (0.61, 1.10) 0.91 (0.58, 1.44) 0.35 0.90 (0.73, 1.13) 0.37
NSMSC Cases/controls 198/373 139/255 30/51
OR (95% CI) 1.0 (ref) 1.10 (0.83, 1.46) 1.25 (0.76, 2.06) 0.34 1.11 (0.85, 1.47) 0.44
Summer (July, Aug., Sept.)
Both cohortsc Cases/controls 113/186 217/348 99/212
OR (95% CI) 1.0 (ref) 1.02 (0.75, 1.38) 0.76 (0.53, 1.09) 0.14 0.82 (0.64, 1.05) 0.12
NYUWHS Cases/controls 77/121 125/190 67/148
OR (95% CI) 1.0 (ref) 1.07 (0.73, 1.56) 0.69 (0.45, 1.07) 0.10 0.80 (0.60, 1.07) 0.14
NSMSC Cases/controls 36/65 92/158 32/64
R (95% CI) 1.0 (ref) 0.99 (0.59, 1.67) 0.89 (0.46, 1.70) 0.72 0.88 (0.52, 1.47) 0.61
aAdjusted for age at menarche (continuous), family history of breast cancer (no or yes), age at first birth/parity (≤ 20, 21-25, 26-30, > 30 years, nulliparous), body
mass index (continuous), hormone replacement therapy use (never or ever), and alcohol consumption (continuous). bOdds ratio (OR) for a doubling in 25(OH)D
level. cAdjusted for cohort in addition to all factors in footnote a. 25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; NSMSC, Northern Sweden Mammary
Screening Cohort; NYUWHS, New York University Women’s Health Study; ref, reference.
Table 3 Odds ratios and 95% confidence intervals for breast cancer risk according to season-adjusted circulating
levels of 25(OH)D (by quintiles and as a continuous variable)
Quintiles Continuous
1 2 3 4 5 Ptrend OR (95% CI)
a P value
Both cohorts
Cases/controls 311/589 362/588 309/588 315/588 288/587
Unadjusted model 1.0 (ref) 1.18 (0.97, 1.43) 0.99 (0.81, 1.21) 1.02 (0.84, 1.24) 0.93 (0.76, 1.14) 0.18 0.94 (0.84, 1.06) 0.31
Adjusted modelb 1.0 (ref) 1.16 (0.95, 1.42) 1.00 (0.81, 1.22) 1.04 (0.85, 1.27) 0.94 (0.76, 1.16) 0.30 0.95 (0.84, 1.08) 0.44
Adjusted modelc 1.0 (ref) 1.16 (0.95, 1.42) 0.99 (0.81, 1.21) 1.03 (0.84, 1.27) 0.94 (0.76, 1.16) 0.27 0.95 (0.84, 1.07) 0.40
NYUWHS
Cases/controls 191/329 190/328 176/329 170/328 166/328
Unadjusted model 1.0 (ref) 0.99 (0.76, 1.29) 0.92 (0.71, 1.20) 0.89 (0.69, 1.16) 0.86 (0.66, 1.12) 0.18 0.91 (0.79, 1.05) 0.21
Adjusted modelb 1.0 (ref) 0.98 (0.75, 1.28) 0.94 (0.72, 1.23) 0.92 (0.70, 1.21) 0.88 (0.67, 1.16) 0.31 0.93 (0.80, 1.08) 0.34
Adjusted modelc 1.0 (ref) 1.00 (0.76, 1.31) 0.95 (0.73, 1.24) 0.93 (0.71, 1.22) 0.90 (0.68, 1.19) 0.37 0.94 (0.81, 1.09) 0.42
NSMSC
Cases/controls 120/260 172/260 133/259 145/260 122/259
Unadjusted model 1.0 (ref) 1.47 (1.09, 1.97) 1.10 (0.81, 1.49) 1.22 (0.90, 1.64) 1.03 (0.75, 1.40) 0.62 1.00 (0.82, 1.23) 0.99
Adjusted modelb 1.0 (ref) 1.48 (1.08, 2.01) 1.09 (0.79, 1.49) 1.26 (0.92, 1.72) 1.05 (0.76, 1.46) 0.74 1.02 (0.82, 1.26) 0.89
Adjusted modelc 1.0 (ref) 1.46 (1.07, 1.99) 1.08 (0.79, 1.48) 1.24 (0.91, 1.70) 1.04 (0.75, 1.45) 0.71 1.01 (0.81, 1.26) 0.94
aOdds ratio (OR) for a doubling in 25(OH)D level. bAdjusted for age at menarche (continuous), age at first birth/parity (≤ 20, 21-25, 26-30, > 30 years, nulliparous),
family history of breast cancer (no or yes), body mass index (continuous), hormone replacement therapy use (never or ever), and alcohol consumption
(continuous). cAdjusted for physical activity and multivitamin use in addition to variables in footnote a. 25(OH)D, 25-hydroxyvitamin D; CI, confidence interval;
NSMSC, Northern Sweden Mammary Screening Cohort; NYUWHS, New York University Women’s Health Study; ref, reference.
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Discussion
In this case-control study nested within two cohorts, we
did not observe an association between circulating 25(OH)
D and breast cancer risk overall. We observed an inverse
association between 25(OH)D and breast cancer risk in
the subgroups of women who were not more than 45
years old or pre-menopausal at blood donation, although
the test for interaction was significant only for menopausal
status. Because of substantial overlap, we were not able to
sort out whether younger age or pre-menopausal status
was driving the association.
Epidemiologic studies on vitamin D and breast cancer
risk have been reviewed recently [31,32]. Traditional
case-control studies [33-39] with blood samples collected
Table 5 Stratified odds ratios and 95% confidence intervals for breast cancer risk according to quintiles of season-
adjusted residual values of circulating 25(OH)D concentration at enrollment
Quintiles
1 2 3 4 5 Ptrend Phet
a
Caucasiansb
Cases/controls 209/399 298/449 270/469 282/473 244/471 0.46 0.31
OR (95% CI) 1.00 1.28 (1.01, 1.62) 1.10 (0.87, 1.38) 1.17 (0.92, 1.48) 0.97 (0.76, 1.24)
Age at enrollment, yearsb
≤ 45 Cases/controls 72/101 54/103 62/103 61/110 52/136
OR (95% CI) 1.00 0.67 (0.42, 1.07) 0.78 (0.49, 1.25) 0.73 (0.46, 1.14) 0.48 (0.30, 0.79) 0.01 0.08
45-54 Cases/controls 118/220 116/220 97/201 117/209 109/186
OR (95% CI) 1.00 0.92 (0.65, 1.29) 0.82 (0.58, 1.17) 0.99 (0.70, 1.40) 1.04 (0.73, 1.48) 0.73
≥ 55 Cases/controls 121/268 192/265 150/284 137/269 127/265
OR (95% CI) 1.00 1.76 (1.30, 2.38) 1.28 (0.94, 1.73) 1.28 (0.94, 1.75) 1.20 (0.87, 1.66) 0.96
Lag-time to diagnosisb
≤ 8 years Cases/controls 123/261 174/240 144/258 140/253 141/252
OR (95% CI) 1.00 1.62 (1.19, 2.22) 1.23 (0.90, 1.69) 1.26 (0.92, 1.73) 1.18 (0.85, 1.63) 0.99 0.30
> 8 years Cases/controls 188/328 188/348 165/330 175/335 157/335
OR (95% CI) 1.00 0.92 (0.71, 1.20) 0.86 (0.66, 1.13) 0.91 (0.70, 1.19) 0.82 (0.62, 1.08) 0.20
ER statusb
ER+ Cases/controls 173/355 219/347 178/358 200/355 78/352
OR (95% CI) 1.00 1.31 (1.00, 1.70) 1.04 (0.80, 1.35) 1.22 (0.93, 1.58) 1.10 (0.83, 1.44) 0.79 0.79
ER- Cases/controls 53/99 60/99 56/111 49/93 54/95
OR (95% CI) 1.00 1.03 (0.63, 1.70) 0.99 (0.60, 1.64) 1.00 (0.61, 1.66) 1.08 (0.64, 1.85) 0.85
Menopausal statusc
Pre-menopausal Cases/controls 150/229 128/228 122/218 123/221 114/238
OR (95% CI) 1.00 0.80 (0.59, 1.09) 0.79 (0.58, 1.08) 0.80 (0.58, 1.09) 0.67 (0.48, 0.92) 0.03 0.05
Post-menopausal Cases/controls 161/360 234/360 187/370 192/367 174/349
OR (95% CI) 1.00 1.48 (1.15, 1.90) 1.16 (0.89, 1.50) 1.22 (0.94, 1.58) 1.21 (0.92, 1.58) 0.67
BMIc, kg/m2
< 25 Cases/controls 115/245 153/312 164/323 195/361 192/403
OR (95% CI) 1.00 1.01 (0.75, 1.36) 1.05 (0.78, 1.40) 1.10 (0.83, 1.47) 0.97 (0.73, 1.29) 0.99 0.56
25+ Cases/controls 187/331 201/267 142/260 115/215 90/171
OR (95% CI) 1.00 1.31 (1.01, 1.70) 0.93 (0.70, 1.22) 0.91 (0.68, 1.22) 0.93 (0.68, 1.27) 0.16
Estrone, pg/mLc, d
< 23.25 Cases/controls 32/90 42/85 40/94 44/97 33/102
OR (95% CI) 1.00 1.38 (0.79, 2.41) 1.19 (0.68, 2.09) 1.36 (0.78, 2.36) 0.95 (0.53, 1.70) 0.83 0.41
23.25-32.45 Cases/controls 43/83 59/82 48/91 53/81 47/74
OR (95% CI) 1.00 1.40 (0.84, 2.33) 1.03 (0.61, 1.73) 1.33 (0.78, 2.25) 1.29 (0.75, 2.22) 0.49
> 32.45 Cases/controls 48/83 80/94 56/80 37/82 41/52
OR (95% CI) 1.00 1.70 (1.05, 2.76) 1.36 (0.81, 2.27) 0.87 (0.50, 1.50) 1.66 (0.94, 2.95) 0.82
aCochran’s Q statistic was used to test for heterogeneity according to lag-time and estrogen receptor (ER) status. bAdjusted for age at menarche (continuous),
family history of breast cancer (yes or no), age at first birth/parity (≤ 20, 21-25, 26-30, > 30 years, nulliparous), body mass index (BMI) (continuous), hormone
replacement therapy use (ever or never), and alcohol consumption (continuous). cUnconditional logistic regression analyses adjusted for cohort and age at
sampling in addition to all factors in footnote b. dMeasured in post-menopausal women only. 25(OH)D, 25-hydroxyvitamin D; CI, confidence interval; OR, odds
ratio.
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after breast cancer diagnosis have found inverse associa-
tions between circulating 25(OH)D and breast cancer
risk. However, changes in lifestyle, particularly physical
activity, following breast cancer diagnosis and treatment
may affect circulating 25(OH)D, and associations
observed in these studies therefore may not reflect pre-
diagnosis associations [32]. Among the 10 prospective
studies published to date, eight reported no association
overall [8-14], one reported a marginally significant
inverse association [16], and one reported a significant
inverse association [15].
In regard to younger and pre-menopausal women,
data from prospective studies are more limited since
eligibility in some of the largest studies was restricted to
older women [8-10]. Among the five prospective studies
that reported results in younger or pre-menopausal
women or both, four reported no association [11-13,16].
In the largest of the four studies, the Nurses’ Health
Study II, which collected blood in relatively young (age
range of 32 to 54 years), mostly pre-menopausal
women, a large number of whom were still pre-meno-
pausal at diagnosis (294 cases), the multivariate-adjusted
OR associated with the top quintile of 25(OH)D was
1.19 (95% CI = 0.77 to 1.84, Ptrend = 0.51). The French
E3N cohort, though, reported a significant inverse asso-
ciation in women who were younger (< 53 years old) at
blood donation, results consistent with ours, and also
observed a non-significant protective association in the
smaller subgroup of women who were pre-menopausal
at diagnosis. The investigators suggested that vitamin D
may act by inhibiting the tumor growth-stimulating
effects of IGF-1 [15]. Because IGF-1 levels decrease with
age, a stronger anticarcinogenic effect of vitamin D
would be expected in younger/pre-menopausal women.
However, our analysis stratifying directly by IGF-1 level
did not support this hypothesis, although the sample
size was limited.
A protective effect of vitamin D on breast cancer
would also be expected to be stronger in pre-menopau-
sal women if vitamin D acts by inhibiting estrogen-sti-
mulated breast cell proliferation [40], since estrogen
levels are much higher before menopause. However, we
found no evidence that the effect of vitamin D varies
according to estrone levels in post-menopausal women,
in spite of the strong positive association between
estrone and breast cancer risk in our study. Moreover,
25(OH)D was not associated with either ER-positive or
ER-negative breast cancer, and this is consistent with
results from other prospective studies of 25(OH)D that
found no difference by ER status [10,13].
Too few subjects had very high concentrations of 25
(OH)D for us to be able to examine the association of
concentrations of at least 100 nmol/L with breast cancer
risk. However, the lack of dose response in the less than
50 to at least 75 nmol/L range (Table 4) suggests that a
true association would have to be of the threshold type,
a hypothesis for which there is little biological support.
A linear dose-response association at levels of not more
than 75 nmol/L has been observed for colorectal cancer,
the one type of cancer for which there is consistent evi-
dence of a protective effect of vitamin D [41].
Several factors that are associated with breast cancer
risk are also associated with circulating 25(OH)D and
therefore could confound the 25(OH)D-breast cancer
association [42]. Dark skin, higher BMI, and lower phy-
sical activity have been repeatedly found to be associated
with lower levels of 25(OH)D, whereas associations
between 25(OH)D and current use of HRT, vitamin
supplements, and alcohol have been less consistent
[28,42,43]. The importance of taking into account these
lifestyle factors was demonstrated in the Women’s
Health Initiative study, in which a significant inverse
association of 25(OH)D with breast cancer risk was atte-
nuated and became non-significant after adjustment for
BMI and physical activity [42]. In our study, we matched
on race/ethnicity (a surrogate for dark skin) and also
conducted analyses limited to Caucasians, and this gave
results similar to the analyses that included all races. As
shown in Tables 3, 4, and 5, adjusting for BMI, HRT
use, physical activity, and multivitamin use had very lit-
tle effect on the ORs. Residual confounding is possible,
particularly by physical activity, for which we classified
women in one of three categories and data were missing
for 11% in the NYUWHS and 38% in the NSMSC.
However, an analysis limited to the subjects for whom
physical activity was available showed very similar
results, as did an analysis adjusting for MET-hours per
week as a continuous variable in the NYUWHS (data
not shown). Another potential source of confounding is
breast cancer screening frequency, as screening visits
that are more frequent could result in earlier diagnosis
of breast cancer or correlate with other health-conscious
behaviors leading to higher 25(OH)D status. However,
because blood donations occurred at the time of mam-
mographic screening visits, number of blood donations
can be considered a proxy for mammographic screening
frequency. We matched on number of blood donations
in the NYUWHS, whereas in the NSMSC, although we
did not match on this variable, 59% of cases had at least
one control who matched exactly on the number of
blood donations, and 89% of cases had at least one con-
trol who matched within ± 1 blood donation. We there-
fore believe that confounding by screening history is
unlikely in our study.
We used residuals obtained by local regression to take
into account seasonal variation. This method has been
used only rarely in studies of 25(OH)D [44], although it
has been used in epidemiologic analyses of other
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biomarkers with temporal variation (for instance, hor-
mones known to vary during pregnancy) [45,46]. In our
study, when the residual method was used, the exposure
value for each woman was the difference between the
absolute level observed for this woman and the pro-
jected mean of 25(OH)D for this day of the year (refer-
ence day). A positive residual indicated that a woman
had a higher-than-average level at this time of the year,
whereas a negative residual indicated a lower-than-aver-
age level. The projected mean was calculated by using
all samples collected in the same cohort on the refer-
ence day, as well as samples taken on neighboring days,
with progressively decreasing weights given to samples
collected further away from the reference day. This
method, therefore, seems well suited to take into
account the gradual changes observed during the
shoulder seasons, when levels progressively increase
(spring) or decrease (fall).
Strengths of this study include its prospective design,
inclusion of two cohorts with different diet and sun expo-
sure, and large sample size. This is also the first study to
include repeat blood samples on a large number of
women. The repeat samples enabled us to assess temporal
reproducibility and gave an indication of the potential
impact of ignoring seasonal variation when studying the
association of circulating vitamin D with disease risk. The
lower ICCs observed when samples were collected in dif-
ferent seasons, compared with the same season, highlight
the importance of taking season into account in the study
design or analysis or both, as other studies have concluded
[47]. The ICC of 0.63 for samples collected 8.0 to 11.7
years apart in the NSMSC compares well with the ICCs of
other biomarkers that have been linked to breast cancer
risk, such as post-menopausal sex hormones. However,
the ICC decreased with increasing time between blood
donations, although this trend did not seem to extend
beyond the first 8 years. This observation underlines that a
single measurement of 25(OH)D is an imperfect reflection
of vitamin D status over the long time period during
which breast cancer develops. Thus, the association of
vitamin D status with breast cancer risk may have been
underestimated because of random error in measurement
of the true exposure of interest (that is, the long-term
average level of 25(OH)D). Another limitation of our
study is the relatively small number of subjects with very
high levels of circulating 25(OH)D (≥ 100 nmol/L).
Conclusions
This large prospective study does not support a relation-
ship between circulating 25(OH)D and risk of breast can-
cer, except possibly in younger women. These results add
to a growing body of evidence from prospective studies
and randomized trials that suggests that higher vitamin D
levels do not reduce breast cancer risk. Recommendations
in regard to vitamin D supplementation should be based
on considerations other than breast cancer prevention,
such as bone health.
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